CPC-027 Cardiovascular Risk Profile of a Spanish HIV-Infected Cohort on Antiretroviral Therapy and the Effect of Protease
Inhibitors

Abstract

Background There is evidence that antiretroviral therapy (ART) increases cardiovascular risk (CVR). The use of protease inhibitors (PIs),
specially indinavir and lopinavir/ritonavir, has been associated with a higher incidence of myocardial infarction.

Purpose To characterise the CVR profile of an HIV-infected cohort on ART from the northwest of Spain. To determinate the effect
of exposure to protease inhibitors (PIs) and exposure time (ET) to ART in CVR.

Materials and Methods Cross-sectional study including HIV patients on ART who were treated at our hospital between March and May 2012. We recorded
demographics, ART history and CVR risk factors. CVR was estimated using the Framingham function calibrated for the Spanish
population (REGICOR). CVR categories were: low (<5%); intermediate (5–9%); high (10–14%); very high (>15%). Five PI exposure
groups were defined: a) no PI exposure (NoPI); b) exposure to PIs but not indinavir or lopinavir/ritonavir (PInoINDnoLPV/r);
c) exposure to indinavir (IND); d) exposure to lopinavir/r (LPV/r); e) exposure to indinavir and lopinavir/r (IND+LPV/r).

Conclusions Our HIV population presents low CVR. Smoking, hypertension and low HDL cholesterol are the outstanding modifiable risk factors
in our cohort. Indinavir exposure and ET to indinavir increases CVR in our population, but no differences were found with
lopinavir/r or other PIs.